 Solution

Fear and anxiety share learning mechanisms, neuromodulators and defensive circuitry, but differ in how threat is specified and sustained. A useful operational distinction is an immediate response to an identified danger versus prolonged anticipation of uncertain danger. That distinction should not be mistaken for a universal division into two independent brain centres. Neuropsychopharmacology is most informative when it compares matched behavioural endpoints and identifies where and when a drug acts.

The first issue is measurement. Freezing, avoidance, autonomic changes, fear-potentiated startle and subjective reports capture different aspects of threat responding. A rat’s reduced open-arm exploration can reflect anxiety, but also altered movement or novelty preference. A smaller startle response can reflect sedation rather than reduced threat processing. It is therefore necessary to measure baseline responsiveness, locomotion and sensory function, and to distinguish acquisition, consolidation, retrieval and expression. A drug administered only at testing does not establish an effect on the original learning.

An influential rat experiment compared potentiation of acoustic startle by a conditioned threat cue with enhancement during sustained bright illumination. Local AMPA receptor antagonism in the central nucleus of the amygdala disrupted the conditioned-cue effect, whereas antagonism in the bed nucleus of the stria terminalis disrupted the light-enhanced effect. The basolateral amygdala contributed to both. This is stronger evidence for differentiation than comparing unrelated assays because the measured reflex was shared. However, conditioning history, stimulus properties and duration differed together, so the result does not isolate duration or uncertainty as the sole cause of the dissociation.^[ref]

The amygdala and BNST belong to interacting networks receiving cortical and other inputs and influencing hypothalamic and brainstem outputs. The hippocampus supplies contextual information and prefrontal cortex can influence threat regulation and extinction retrieval. Subdivisions and projection-defined populations within the extended amygdala can differ in function. A general claim that the amygdala produces all fear and the BNST produces all anxiety consequently ignores shared pathways, task dependence and cellular heterogeneity.

Fast inhibitory signalling supplies an important pharmacological comparison. Many benzodiazepines positively modulate susceptible GABA-A receptors, but anxiolysis must be distinguished from sedation and amnesia. A controlled human crossover study compared predictable-cue, unpredictable-threat and no-threat conditions. Alprazolam reduced sustained contextual startle enhancement at the effective tested treatment condition while leaving phasic cue potentiation relatively unaffected. The design included an active sedating comparison as well as placebo. This supports psychopharmacological differentiation between sustained and phasic measures; it does not prove absolute drug selectivity for a subjective state or show that every clinical anxiety presentation has the same mechanism.^[ref]

Serotonin illustrates why transmitter identity alone is insufficient. Reuptake inhibition affects multiple receptors and projection targets, and early effects can differ from adaptations after repeated treatment. In mice, a dorsal-raphe projection to the BNST recruited a serotonin-sensitive local circuit and promoted selected threat-related behaviours. This provides a pathway-specific explanation for an anxiogenic effect of increasing serotonin signalling, compatible with different effects at other targets. It is not evidence that serotonin uniformly causes anxiety or that rodent threat responses establish the clinical time course of an SSRI.^[ref]

Receptor subtype and developmental timing also matter. The same receptor class can act as an autoreceptor controlling raphe output or on non-serotonergic target neurons. Norepinephrine, corticotropin-releasing hormone and other modulators interact with these systems rather than map one-to-one onto fear or anxiety. Local circuit effects should not be inferred from circulating hormone concentrations. A mechanistic explanation should state the receptor, target, timescale and outcome, not merely whether a brain-wide chemical level rose or fell.

Learning about safety supplies both a shared mechanism and a therapeutic distinction. In extinction learning, an expected aversive outcome is omitted; reduced responding can reflect new inhibitory or contextual knowledge rather than deletion of the original association. In rats, the NMDA receptor partial agonist D-cycloserine facilitated later reduction of conditioned startle when combined with extinction training. Its effect depended on learning conditions rather than acting simply as an acute suppressant of every defensive response. This motivates a learning-adjunct strategy, but the animal result alone cannot establish clinical efficacy.^[ref]

Anxiety about uncertain contexts can involve more than a response to one cue: broad threat generalization, avoidance that prevents corrective experience, and context-dependent retrieval may sustain it. Conversely, a sharply defined learned cue can acquire persistent control. Exposure therapy therefore cannot be reduced to suppressing an output on one occasion. An intervention that changes expression without improving subsequent safety learning might have a different long-term effect from one that changes what is retained. Renewal after extinction also predicts that improvement in one context need not transfer automatically to another.

The strongest comparison is thus dimensional and mechanistic. Fear and anxiety share synaptic plasticity, inhibitory signalling and distributed threat networks, while particular temporal and informational demands recruit distinguishable components. Drug and circuit dissociations are meaningful when matched controls rule out motor or sensory explanations; they should refine this network account rather than replace it with a pair of transmitter labels. These are conclusions about evidence and experimental models, not instructions for selecting medication.